Novozymes A/S
CSE:NZYM B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
346.4
419.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Novozymes A/S
Novozymes A/S
Accrued Liabilities
Novozymes A/S
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novozymes A/S
CSE:NZYM B
|
Accrued Liabilities
kr820m
|
CAGR 3-Years
12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Chr Hansen Holding A/S
CSE:CHR
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Photocat A/S
STO:PCAT
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Novozymes A/S
Glance View
Novozymes A/S is a global leader in biotechnology, focusing on the production of enzymes and microorganisms that enhance industrial processes. Founded in 1925 and based in Denmark, the company has consistently leveraged its deep scientific expertise to innovate solutions across various sectors, including agriculture, bioenergy, and food & beverage. By developing sustainable alternatives to traditional chemical processes, Novozymes not only improves efficiency for its clients but also helps minimize environmental impact. As industries continue to shift towards greener practices, Novozymes stands at the forefront of this transition, positioning itself as a pivotal player committed to driving sustainable development. For investors, Novozymes represents a compelling opportunity in a growing market driven by increasing awareness of sustainability and resource efficiency. The company boasts a diverse portfolio of products and a strong track record of profitability, sustained by its continuous investment in research and development. With a robust customer base spanning across more than 30 industries, Novozymes is well-equipped to capitalize on the expanding demand for bio-based solutions. Investors can find confidence in Novozymes' strategic focus on innovation and its ability to adapt to the evolving landscape of global sustainability goals, making it a strong candidate for those looking to invest in a future-oriented enterprise.
See Also
What is Novozymes A/S's Accrued Liabilities?
Accrued Liabilities
820m
DKK
Based on the financial report for Dec 31, 2023, Novozymes A/S's Accrued Liabilities amounts to 820m DKK.
What is Novozymes A/S's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
3%
Over the last year, the Accrued Liabilities growth was 18%. The average annual Accrued Liabilities growth rates for Novozymes A/S have been 12% over the past three years , 3% over the past five years .
You don't have any saved screeners yet
